These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11792060)

  • 1. Immune responses to measles and measles vaccine: challenges for measles control.
    Moss WJ; Polack FP
    Viral Immunol; 2001; 14(4):297-309. PubMed ID: 11792060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies.
    Coughlin MM; Beck AS; Bankamp B; Rota PA
    Viruses; 2017 Jan; 9(1):. PubMed ID: 28106841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
    Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
    J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits.
    Mina MJ
    J Infect; 2017 Jun; 74 Suppl 1():S10-S17. PubMed ID: 28646947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles eradication: is it in our future?
    Orenstein WA; Strebel PM; Papania M; Sutter RW; Bellini WJ; Cochi SL
    Am J Public Health; 2000 Oct; 90(10):1521-5. PubMed ID: 11029981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.
    Moss WJ; Scott S; Mugala N; Ndhlovu Z; Beeler JA; Audet SA; Ngala M; Mwangala S; Nkonga-Mwangilwa C; Ryon JJ; Monze M; Kasolo F; Quinn TC; Cousens S; Griffin DE; Cutts FT
    J Infect Dis; 2007 Aug; 196(3):347-55. PubMed ID: 17597448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National serologic survey of measles immunity among persons 6 years of age or older, 1988-1994.
    Hutchins SS; Redd SC; Schrag S; Kruszon-Moran D; Wooten K; McQuillan GM; Bellini W; Meyer PA; Hadler S
    MedGenMed; 2001 Jan; ():E5. PubMed ID: 11320344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging diseases: measles.
    Ota MO; Moss WJ; Griffin DE
    J Neurovirol; 2005 Oct; 11(5):447-54. PubMed ID: 16287686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population immunity to measles in the United States, 1999.
    Hutchins SS; Bellini WJ; Coronado V; Jiles R; Wooten K; Deladisma A
    J Infect Dis; 2004 May; 189 Suppl 1():S91-7. PubMed ID: 15106096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles elimination: progress and challenges.
    Cutts FT; Henao-Restrepo A; Olivé JM
    Vaccine; 1999 Oct; 17 Suppl 3():S47-52. PubMed ID: 10559534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global measles elimination efforts: the significance of measles elimination in the United States.
    Strebel PM; Henao-Restrepo AM; Hoekstra E; Olive JM; Papania MJ; Cochi SL
    J Infect Dis; 2004 May; 189 Suppl 1():S251-7. PubMed ID: 15106119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of improving the efficacy of measles vaccine.
    Garly ML; Aaby P
    Acta Trop; 2003 Jan; 85(1):1-17. PubMed ID: 12505179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune activation at effector and gene expression levels after measles vaccination in healthy individuals: a pilot study.
    Dhiman N; Ovsyannikova IG; Oberg AL; Grill DE; Jacobson RM; Poland GA
    Hum Immunol; 2005 Nov; 66(11):1125-36. PubMed ID: 16571413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey.
    Lowther SA; Curriero FC; Kalish BT; Shields TM; Monze M; Moss WJ
    Lancet; 2009 Mar; 373(9668):1025-32. PubMed ID: 19211140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine.
    Wong-Chew RM; Beeler JA; Audet S; Santos JI
    J Med Virol; 2003 Jun; 70(2):276-80. PubMed ID: 12696117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.
    Song MK; Vindurampulle CJ; Capozzo AV; Ulmer J; Polo JM; Pasetti MF; Barry EM; Levine MM
    J Virol; 2005 Aug; 79(15):9854-61. PubMed ID: 16014946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The theory of measles elimination: implications for the design of elimination strategies.
    Gay NJ
    J Infect Dis; 2004 May; 189 Suppl 1():S27-35. PubMed ID: 15106086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on immune effect of different measles vaccine among 196 infants at age of 8-month in Yunnan Province].
    Tang JJ; Ding ZR; Pang YK
    Zhongguo Yi Miao He Mian Yi; 2009 Aug; 15(4):323-6. PubMed ID: 20077730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate age for measles vaccination in the United States.
    Orenstein WA; Markowitz L; Preblud SR; Hinman AR; Tomasi A; Bart KJ
    Dev Biol Stand; 1986; 65():13-21. PubMed ID: 3549395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.